As always, I assume this will take time to come into routine clinical use, but it is exciting to see a truly new class of medication in this field. I anticipate that further studies will be forthcoming.
FDA Approves Platelet-Receptor Antagonist Vorapaxar — Physician’s First Watch
FDA Approves Platelet-Receptor Antagonist Vorapaxar
By Larry Husten
The FDA has approved vorapaxar (Zontivity), an oral platelet-receptor antagonist, to reduce the risk for MI, stroke, cardiovascular death, and the need for revascularization in people with a history of MI or peripheral arterial disease.
The first in a new drug class known as protease-activated receptor-1 (PAR-1) antagonists, vorapaxar prevents platelet aggregation. However vorapaxar also increases bleeding risks — its principal side effect — and thus is contraindicated in those with a history of stroke, TIA, or intracranial bleeding.
In announcing the approval, the FDA said the drug lowered the risk for heart attack, stroke, and cardiovascular death in the target population from 9.5% to 7.9% over a 3-year period.
Adapted from CardioExchange